

Media Release

Zug, 24 October 2017

Y-mAbs Therapeutics closes USD 50 million financing round led by HBM Healthcare Investments

Y-mAbs Therapeutics, a privately held immunotherapy company discovering and developing innovative treatments for patients with cancer, today announced the closing of a private placement raising USD 50 million. HBM Healthcare Investments, who led the round, contributed USD 20 million in this financing. Dr. Michael Buschle of HBM Partners will join the Board of Y-mAbs.

Dr. Andreas Wicki, Chief Executive Officer of HBM Healthcare Investments comments: *“Y-mAbs’ approach to immunotherapy shows great promise and will further advance innovation and product development in the pediatric oncology field. We are delighted to add this young and rapidly growing company to our portfolio and to support and accompany it on the way to further success.”*

Y-mAbs lead compound in clinical testing, Burtomab, is an antibody that is broadly reactive with human solid tumors, including embryonal tumors, carcinomas, sarcomas and brain tumors. In June 2017, the company announced positive top line results from a potentially pivotal study of ¹³¹I-burtomab in Refractory Leptomeningeal Metastasis from Neuroblastoma. Results showed a 58 month average survival for the patients treated with ¹³¹I-burtomab in the study, compared to an average of 4.7 month and no long term survival or cure, for a contemporary cohort in the Central German Childhood Cancer Registry. After more than a decade of follow-up, data shows more than 40% overall long term survival indicating that the treated children have been cured. Burtomab has been granted Breakthrough Therapy Designation by the FDA in June 2017.

For further information, please contact Dr Andreas Wicki on +41 41 710 75 77, or at andreas.wicki@hbmhealthcare.com

About Y-mAbs

Y-mAbs is a clinical stage biopharmaceutical company focused on developing new cancer treatments through immunotherapies. In addition, Y-mAbs utilizes its platform technologies to

NOT FOR DISTRIBUTION IN THE USA, CANADA, JAPAN OR AUSTRALIA

HBM Healthcare Investments

create next-generation humanized, affinity matured bispecific antibodies targeting GD2 and B7H3. To further improve the bispecific antibodies, Y-mAbs is collaborating on the development of a novel human protein tag that dimerizes T-cell engaging bispecific antibodies, which enables higher tumor binding and results in a longer serum half-life and a significantly greater T-cell mediated killing of tumor cells. Y-mAbs' goal is to drive multiple product candidates in select solid tumor cancers to FDA approval. Each candidate has the potential to treat a variety of high-risk cancers.

To learn more, visit www.ymabs.com.

Information on HBM Healthcare Investments Ltd

HBM Healthcare Investments invests in the healthcare sector. The Company holds and manages an international portfolio of promising companies in the human medicine, biotechnology, medical technology and diagnostics sectors and related areas. Many of these companies have their lead products already available on the market or at an advanced stage of development. The portfolio companies are closely tracked and actively guided in their strategic direction. This is what makes HBM Healthcare Investments an interesting alternative to investments in big pharma and biotechnology companies. HBM Healthcare Investments has an international shareholder base and is listed on SIX Swiss Exchange (ticker: HBMN).

Disclaimer

This media release does not constitute an issue prospectus within the meaning of Art. 652a or Art. 1156 of the Swiss Code of Obligations, a listing prospectus in the sense of the SIX Swiss Exchange Listing Rules or a securities prospectus as defined in the German Securities Prospectus Act (*Wertpapierprospektgesetz*). Publication is for information purposes only and constitutes neither an offer to sell nor an invitation to buy or subscribe for securities. This media release and the information it contains must not be distributed or forwarded to or within the United States of America (USA) or to US persons (including legal entities) or publications with a general circulation in the USA. This media release does not constitute an offer or invitation to purchase any securities in the USA. The securities of HBM Healthcare Investments Ltd have not been registered under United States securities legislation and may not be offered, sold or delivered within the USA or to US persons without prior registration or the corresponding exemption from the registration requirements of US securities legislation.

HBM Healthcare Investments Ltd

Bundesplatz 1 | CH-6300 Zug | Tel: +41 41 710 75 77 | Fax: +41 41 710 75 78 | info@hbmhealthcare.com
www.hbmhealthcare.com